Cathie Wood and Ark Invest have significantly increased their stake in Tempus AI, with the innovation-focused investment firm acquiring over 600,000 shares across its funds since the start of 2025.
Ark Invest's interest in TEM began on December 6, when the ARK Genomic Revolution ETF made its initial purchase of shares in the healthcare technology company. Since then, Tempus AI has rapidly ascended within Ark's portfolio, becoming the tenth largest holding in the flagship ARK Innovation ETF . TEM now represents 3.2% of ARKK's total assets, with a market value exceeding $265 million.
Additionally, Tempus is the fourth-largest position in the ARK Genomic Revolution ETF, accounting for 5.64% of the fund's portfolio, with a market value nearing $68 million.
In January 2025, Ark Innovation ETF expanded its position in TEM, acquiring 439,536 shares, while ARKG also increased its holdings, purchasing an additional 179,255 shares during the same period.
Tempus AI is currently up 62% year-to-date.
In 2025, Wood’s ARKK is up by 10% and ARKG is up on the year by 17%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.